Recce Pharmaceuticals Ltd (ASX:RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics designed to address the urgent global health problem of antibiotic resistant superbugs.
Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms.
Find out more from James Graham at Proactive's CEO Sessions.
Click below to register by email
- Melbourne: Wednesday 31st January.
- Sydney: Thursday 1st February.
- Call office on (02) 9280 0700.
Presenter list
Reward Minerals (ASX:RWD): Greg Cochran
Recce Pharmaceuticals (ASX:RCE): James Graham
Rimfire Pacific Mining (ASX:RIM): John Kaminsky
More companies to be released in coming days!